Beta Drugs Ltd responds to NSE query on significant share price movement, confirming no undisclosed sensitive information.
Company attributes price volatility to market-driven factors beyond its control, with no material events pending.
Affirms compliance with SEBI LODR Regulation 30 and commitment to timely disclosures of material information.